Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma
OBJECTIVES: I. Determine the clinical response in patients with metastatic ocular melanoma
treated with gp100:209-217 (210M) antigen and MART-1:26-35 (27L) antigen emulsified in
II. Determine the clinical benefit of interleukin-2 in combination with this vaccine in
PROTOCOL OUTLINE: Patients receive vaccine subcutaneously once weekly. Treatment repeats
every 4 weeks for a total of 6 courses in the absence of disease progression or unacceptable
Patients with progressive disease may receive vaccine SC on day 1 followed by interleukin-2
IV over 15 minutes every 8 hours for a maximum of 12 doses. Treatment repeats every 3 weeks
for at least 4 courses in the absence of disease progression or unacceptable toxicity.
A total of 15-25 patients will be accrued for this study within 1 year.
Primary Purpose: Treatment
Francesco M. Marincola
National Cancer Institute (NCI)
United States: Federal Government
|Surgery Branch||Bethesda, Maryland 20892|